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ABSTRACT
Aim: To assess the long-term cost-effectiveness of an atrial fibrillation disease management program
(i.e. the SAFETY program) from the Australian healthcare system perspective.
Methods: A multistate Markov model was developed based on patient-level data from the SAFETY
randomized controlled trial. Predicted long-term survival, dependent on hospital admission history,
was estimated by extrapolating parametric survival models. Quality-adjusted life years (QALY) and life
years (LY) were the primary and secondary outcome measures used to estimate the incremental cost-
utility/effectiveness ratio (ICUR/ICER). Both deterministic and probabilistic sensitivity analyses (PSA)
were undertaken.
Results: The SAFETY program was associated with both higher costs ($94,953 vs. $78,433) and bene-
fits [QALY (3.99 vs 3.60); LY (5.86 vs 5.24)], with an ICUR of $42,513/QALY or ICER of $26,356/LY, com-
pared to standard care. Due to the extended survival, the SAFETY was associated with a greater
number of hospitalizations (14.85 vs 11.65) and higher costs for medications ($25,084 vs $22,402) and
outpatient care ($12,904 vs $11,524). The cost per hospitalization for an average length of stay, analyt-
ical time horizon, and cost of medication are key determinants of ICUR. The PSA showed that the
intervention has a 70.4% probability of being cost-effective at a threshold of $50,000/QALY.
Conclusions: The SAFETY program has a high probability of being cost-effective for patients with
atrial fibrillation. It is associated with uncertainty that further research could potentially eliminate;
implementation with further evidence collection is recommended.
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Atrial fibrillation (AF) is the most common form of cardiac
arrhythmia observed in medical practice1 and is associated
with detrimental consequences, including heart failure (HF),
ischemic stroke, and mortality. It also imposes a great eco-
nomic burden on society. For example, in Australia, it affects
approximately 400,000 people, with aging as a prominent
risk factor. In 2014–2015, there were 58,608 hospitalizations
for AF as a principal diagnosis (National Hospital Morbidity
database), and  20–25% of patients with AF are admitted
to hospital annually. Caring for AF costs the Australian econ-
omy over AU$1.25 billion per year through medical costs,
long-term care costs for those with a stroke-related disability,
and lost productivity output2,3. Internationally, the Global
Burden of Disease study4 estimated that, in 2010, there were
33.5 million patients with AF in the world, constituting 
0.5% of the total world population5. The projected
worldwide population ageing, combined with an accumula-
tion of cardiovascular diseases and lifestyle risk factors,
ensures a likely and dramatic increase in the number of
patients with AF (primarily the non-valvular AF, NVAF) in the
coming years. Given its prevalence and the severe complica-
tions associated with it, AF is considered one of the major
threats to cardiovascular health6.
Management of NVAF includes five components that tar-
get different sections of the heart: acute stabilization of
patients who present with NVAF complications or hemo-
dynamic compromise; detection and treatment of underlying
and accompanying cardiovascular conditions; stroke risk
assessment and oral anticoagulation for stroke prevention;
rate control; and rhythm control therapy. However, adher-
ence to treatment is generally considered suboptimal. For
example, an Australian study found that nearly half of the
patients with NVAF did not adhere to the prescribed
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treatment7–9, rendering them at higher risk of developing
cardiovascular complications, including stroke.
A nurse-coordinated multidisciplinary program has signifi-
cant potential to promote the management of patients with
NVAF, with the role of a NVAF nurse outlined in the most
recent European guidelines10. It could involve a home-based,
NVAF-specific management strategy (including greater clin-
ical surveillance and longer-term support) with an aim to
optimize antiplatelet/thrombotic treatment, preserve cardiac
function, and improve clinical stability11. A randomized con-
trolled trial (RCT) of a multidisciplinary disease management
program aiming to improve NVAF patients’ adherence to
treatment reported that this multicomponent service was
associated with proportionately more days alive and out of
hospital but observed no impact on all-cause mortality rela-
tive to standard management, and a potential to improve
poor health outcomes in patients admitted with chronic
NVAF12. A within-trial economic analysis was undertaken to
assess the short-term cost-effectiveness of this disease man-
agement program and showed that, compared with standard
management, this intervention is a potentially dominant
strategy for NVAF patients (i.e. –$4,375 and 0.02 quality-
adjusted life year gains per patient)13. Given that lifetime
management is foreseeable for patients with NVAF, ascertain-
ing the long-term cost-effectiveness of this service program
would complement its economic credentials and provide a
more comprehensive examination of the long-term costs and
benefits, which is required if it is to be scaled up to the
national level and seek public subsidy.
This study aimed to undertake a modelled economic
evaluation for the disease management program that tar-
geted patients with NVAF to assess its long-term cost-effect-




The details of the SAFETY program were reported else-
where12. Briefly, the SAFETY program was a structured post-
discharge intervention delivered by a senior specialist nurse
consisting of a home visit 7–14 days after discharge ensued
by a series of repeated home visits, scheduled clinical
reviews, and telephone follow-up. The aim of the program
was to optimize both drug treatment and non-pharmaco-
logical management.
Model structure
A multi-state Markov model, consisting of five Markov health
states, was developed to simulate the long-term health out-
come and costs associated with the NVAF disease manage-
ment program (i.e. the SAFETY program). The five health
states were: alive without hospitalization, alive post first hos-
pitalization, alive post second hospitalization, alive post third
hospitalization, and dead.
All patients entered the model in the alive without hospi-
talization state and could then (i) remain event-free; (ii) be
hospitalized, or (iii) die due to all causes in quarterly (3-
month) cycles. Patients experiencing more than three hospi-
talizations were aggregated into the “alive post-third hospi-
talization” health state.
Given that patients requiring frequent hospital care are
indicative of persistent and refractory NVAF that can predict
the long-term prognosis14, the alive post n number of hospi-
talizations states (i.e. one, two, or three) were modelled sep-
arately to account for this difference. A half-cycle correction
was applied to adjust for both costs and benefits (i.e. all
transitions were assumed to occur in the middle of the cycle;
if patients died during a cycle, only half of the costs and
benefits would be accrued). Costs and benefits were dis-
counted at a rate of 5% according to the Australian guideline
for preparing submission (including economic evaluation) to
the Pharmaceutical Benefits Advisory Committee (the
national agency for pharmaceutical reimbursement)15. The
model structure is illustrated in Figure 1. TreeAge software
was utilized for the modelling analysis (TreeAge Pro 2019,
TreeAge Software, Williamstown, MA).
Modelled population
The modelled population were Australian patients diagnosed
with chronic NVAF but not chronic heart failure, according to
Figure 1. Illustration of multi-state Markov model.
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international guidelines16. The population characteristics
were the same as of those recruited in the RCT: equal pro-
portions of male and female participants with a mean age of
72 years and 90% experiencing persistent NVAF, 64% being
managed by a rate-control strategy, and 33% having a co-
morbid coronary heart disease12. The time horizon was set at
10 years, given the average age of the population modelled.
The comparator was the standard care (i.e. current clinical
practice in Australia, including routine medical care, hospital
care, and pharmacotherapy) for patients with NVAF, which is
consistent with the pivotal RCT12. For the standard care arm,
patients were managed predominantly by a General
Practitioner (GP) in consultation with a specialist doctor and
received medications including warfarin, antiplatelet agents,
antiarrhythmic drugs12. More recent oral anticoagulants (e.g.




All the transition probabilities – including probabilities of first
hospitalization, recurrent hospitalization, and death due to
all causes dependent on number of re-hospitalizations (i.e.
overall survival) – were generated from time-to-event analy-
ses using individual patient data (IPD) from the pivotal RCT.
For the derivation of transition probabilities over the trial
duration (i.e. the minimum follow-up of 2 years), the Kaplan-
Meier survival analysis was adopted to estimate the survival
function for the first 900 days. Finally, parametric survival
analysis was undertaken to base extrapolation of transition
probabilities beyond the trial follow-up period.
A multi-state time to event modelling approach17 was
adopted to statistically estimate the following transition
probabilities:
i. No further event to first hospitalization;
ii. No further event to death;
iii. Post first hospitalization to second hospitalization;
iv. Post first hospitalization to death;
v. Post second hospitalization to third hospitalization;
vi. Post second hospitalization to death;
vii. Post third hospitalization to death.
A multistate modelling technique was chosen because (1)
it is often used to model complex disease profiles by
accounting for competing events at each transition (i.e. a sin-
gle patient faces the risks of rehospitalization and death sim-
ultaneously) and (2) it allows the use of patient-level data,
offers flexibility to extrapolate each transition by a variety of
parametric models, and possibly enables parameter sharing
across transitions. Specifically, the STATA code provided by
Crowther and Lambert17 was adapted to derive the afore-
mentioned transition probabilities over the SAFETY
trial duration.
For the time to death/hospitalization analysis (i.e. transi-
tion probabilities i to vii), exponential, Weibull, loglogistic,
lognormal, and Gompertz distributions were fitted to the IPD
with respect to the particular dataset. The best fit distribu-
tion was selected based on predefined criteria18,19. To esti-
mate the transition probabilities for the within-trial period,
the following formula was employed using estimates from
Kaplan-Meier survival functions20:
transition probabilityt1  t
¼ ðsurvival functiont1survival functiontÞ
survival functiont1
After 900 days, the SAFETY program and standard care
groups were assumed to have identical transition probabil-
ities (i.e. no treatment). All IPD-level analysis was performed
by STATA version 15 (StataCorp. Statistical Software: Release
15, College Station, TX: StataCorp LP).
Costs and utility weights
Costs and utility weights were sourced from the trial data,
from the perspective of costs to the Australian healthcare
system. Correspondingly, those incorporated in the model
included costs relating to hospitalization, medications, out-
patient care (i.e. visits to primary care physician/specialist,
examinations, etc.), and disease management services. The
cost due to hospitalization was adjusted by the probability
of prolonged/average length of stay (LoS). Since there is no
significant between-group difference in the hospitalization
cost, the same cost per hospitalization (based on hospitaliza-
tion presentation diagnostic related group) was applied.
Particularly, the average LoS and cost of hospitalization
thereof were calculated across the entire sample regardless
of randomization status. Then, the probability of prolonged
LoS (i.e. proportion of individuals with LoS longer than the
average LoS) was derived from the IPD by randomized
groups (given that this is significantly different between the
groups), whereas the average cost of hospitalization for a
prolonged LoS was computed across all individuals with pro-
longed LoS irrespective of their group status. All costs were
valued in the year 2018 and corresponding consumer price
indices (CPI) from the health sector were used to inflate the
costs not derived from 2018.
Disutility associated with hospitalization was derived from
the trial data. In order to derive the utility decrement associ-
ated with repeated rehospitalizations, a regression analysis of
utility at 24months was undertaken with number of rehospi-
talizations as the predictor (i.e. entered as dummy variable)
regardless of randomized groups. The quality-adjusted life
years (QALY) were then estimated based on the utility
weights attached to the health states multiplied by the time
spent in each health state. The life years (LY) gained were
also calculated. Since no adverse effects associated with this
management program intervention were reported, no costs
in relation to adverse effects were included in the model.
The unit costs and utility weights are summarized in Table 1.
Cost-utility and cost-effectiveness analysis
Cost utility analysis was undertaken by calculating the incre-
mental cost-utility ratio (ICUR) from the difference in costs
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divided by the difference in QALY for the SAFETY program
vs the standard care. Similarly, the incremental cost-effective-
ness ratio (ICER) was also estimated using LY gain as the out-
come measure. The often-quoted willingness-to-pay per
QALY/LY of $50,000 in Australia was utilized to assess the
cost-effectiveness of the intervention21.
Sensitivity analysis
Deterministic (DSA) and probabilistic sensitivity analyses
(PSA) were performed to test the robustness of base case
results. For DSA, a series of one-way sensitivity analyses were
undertaken by varying key model parameters within a range
(based on the best available evidence or assumptions). The
results from the one-way sensitivity analyses are shown as
Tornado diagrams, sequentially graphing the variable with
the largest impact on the cost-utility results. PSA was per-
formed to assess the overall impact of uncertainty in the
model by defining distributions for the key parameters (i.e.
variables regarding transition probabilities, utilities, and
costs). The uncertainty around parameters (i.e. lambda for an
exponential distribution; lambda and gamma for a Gompertz
distribution) defining the parametric survival functions was
also examined by incorporating the distribution for these
parameters. Finally, 5,000 iterations (i.e. second-order Monte
Carlo simulation) were run to construct a mean and 95%
credible interval (CI) for the corresponding cost and benefit,
and the results were plotted on a cost-effectiveness plane
and cost-effectiveness acceptability curve.
Value of perfect information
The uncertainty in the results was further examined using
the value of information technique to quantify the expected
value of perfect information (EVPI). The EVPI denotes a theor-
etical monetary value from future research that would
remove all measured uncertainty included in the analysis
(e.g. parameter uncertainty around transition probability,
cost, and utility weights)22. The EVPI per person is calculated
as the difference between the net monetary benefit (NMB,
which represents the value of an intervention in monetary
terms with a positive value indicating the intervention being
cost-effective) of the proposed intervention across all itera-
tions (i.e. all sampled iterations from PSA) and the NMB of
each individual iteration (i.e. one sampled iteration). For
example, if 5,000 iterations (i.e. 5,000 sampled estimates per
parameter from a single distribution) are run for the PSA and
the NMB from one single iteration is the same as the overall
average NMB (i.e. mean of all iterations), its EVPI value is
zero. However, when these two NMBs are not identical, there
is some value to eliminating the uncertainties being simu-
lated (i.e. the difference between the iteration NMB and the
mean NMB). The total EVPI is then estimated by multiplying
the per-person EVPI by the estimated number of incident
NVAF hospital admissions (i.e. 35,000 in Australia per
annum3,23) and the useful life of the new technology (in this
case, the assumed minimum number of years the NVAF dis-
ease management program is likely to be standard practice,
4 years) with the value that accrues in future years dis-
counted at 5%21.
Results
Transition probabilities and costs
The transition probability over the trial duration was directly
calculated from the corresponding Kaplan-Meier curve
(Supplementary Figures S1–S3). As to the long-term extrapo-
lation, except for transition probability ii (where the
Gompertz distribution was selected), the exponential distri-
bution was chosen to extrapolate the long-term transition
probabilities. Details on the parametric survival analysis and
model selection for extrapolation are provided in Tables 2
and 3 and Supplementary Figures S4–S7. Intervention mem-
bership-specific transition probabilities were employed
regardless of significance in between-group differences. The
transition probabilities for the trial duration are detailed in
Supplementary Table S1.
Cost-utility and cost-effectiveness analysis
The base case result showed that the SAFETY program was
associated with both higher costs ($16,520) and greater ben-
efits (0.39 QALY and 0.62 LY gains, respectively), compared
to the standard care group. The total cost of care for
patients with NVAF was $94,953 in the SAFETY program vs
$78,433 in standard care groups, which included total cost of
hospitalizations ($56,377 vs $44,506), medications ($25,084 vs
Table 1. Costs and utility weight used in the model.
Cost Cost per cycle/event Range Source
Cost of SAFETY program $738 0–$1,476 SAFETY RCT
Cost of hospitalization with ALoS $4,053.05 0–$8,106 SAFETY RCT
Cost of hospitalization with PLoS $6,834.74 0–$13,669 SAFETY RCT
Cost of medications $1,070 0–$4,279 SAFETY RCT
Cost of outpatient care $550 0–$3,001 SAFETY RCT
Utility of NVAF 0.7381 0.60–1.00 SAFETY RCT
Disutility of first rehospitalization –0.03715 0–0.06512 SAFETY RCT
Disutility of second rehospitalization –0.01821 0–0.06512 SAFETY RCT
Disutility of third rehospitalization –0.02769 0–0.06512 SAFETY RCT
Proportion of prolonged LoS
SAFETY program 0.1883 0–0.3766 SAFETY RCT
Standard of care 0.2187 0–0.4374 SAFETY RCT
Abbreviations. ALoS, average length of stay; PLoS, prolonged length of stay; NVAF, atrial fibrillation.After 900 days, the proportion of prolonged LoS was the same across the two groups.
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$22,402), and outpatient care ($12,904 vs $11,524). With
regard to the outcome measure, subjects from the SAFETY
program arm achieved both greater QALY (3.99 vs 3.60) and
LY (5.86 vs 5.24) gains. However, due to the marginally lon-
ger quality-adjusted survival (i.e. 0.63 LY  7.6months),
patients assigned to the SAFETY program are likely to have
more hospitalizations ( 3 hospitalizations). Finally, the ICUR
and ICER are $42,513/QALY and $26,356/LY, respectively,
which suggests the SAFETY program is cost-effective for
patients with NVAF from an Australian healthcare perspective
over a life-time horizon (Table 4).
Sensitivity analysis
The DSA showed that the ICUR was sensitive to the cost of
hospitalization due to average LoS, time horizon, cost of
medication, and outpatient care. Utility of NVAF, utility decre-
ment of hospitalization, and discount rate also contributed
to the variation in ICUR to a lesser extent (Figure 2). The DSA
for the effectiveness outcome (i.e. LY) suggested that the
ICER was most sensitive to the cost of hospitalization due to
average LoS and the time horizon (Supplementary
Figure S8).
Generally, the results from the PSA were comparable to
the base case analysis (Table 4). The incremental cost-effect-
iveness plane (Figure 3) showed that the SAFETY program
has a probability of 70.4% of being cost-effective compared
to the standard care at a WTP/QALY threshold of $50,000.
The cost-effective acceptability curve (Figure 4) suggested
that if the WTP/QALY threshold is greater than $75,000 the
intervention has a high likelihood (>90.7%) of being a cost-
effective intervention for patients with NVAF.
Value of perfect information
By incorporating all parameter uncertainty in terms of transi-
tion probabilities, costs and utility weights, the total value of
perfect information for the SAFETY program amounted to
$217 million and, in contrast, the NMB was $14 billion over
the same period. Where the cost of further research is likely
to be less than $217 million, it is suggestive that further
research is warranted. However, given the positive and large
NMB (including the opportunity cost associated with delay-
ing implementation of a service that provides patient survival
gain), implementation with further evidence collection is the
recommended strategy24.
Discussion
The results from this modelled economic evaluation show
that the SAFETY program has a high probability (>70.4%) of
being cost-effective in patients with NVAF from the
Australian healthcare system perspective. Its implementation
Table 2. Results of model fitness for the parametric survival analyses.
Distribution AIC BIC










































Abbreviations. Hosp, hospitalization; AIC, Akaike Information Criterion; BIC,
Bayesian Information Criterion.
Table 3. Parameters for the parametric survival models applied for the long-term extrapolation.
Parametric survival distribution Parameters
Mean SD
No event to death Exponential lambda 8.255915 0.3333
First hospitalization to death Exponential lambda 8.058327 0.4472
Second hospitalization to death Exponential lambda 7.77073 0.4472
Third hospitalization to death Exponential lambda 8.257998 0.3015
No event to first hospitalization Weibull Cons 0.2410344 0.0480
p 0.7858146 0.0377
First hospitalization to second hospitalization Weibull Cons 2.844625 0.7110
p 0.7024144 0.0692
Second hospitalization to third hospitalization Exponential lambda 4.218297 0.5705
Lambda is the exponential form of the value presented here, for example, lambda¼ exp(–8.826905). For Weibull distribution, p is the
shape parameter; exp(cons) is the scale parameter.
Abbreviation. SD, standard deviation.
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is associated with both higher cost and greater benefits. Due
to the increased life expectancy, which may be attributed to
better management of NVAF via improved prescription of
evidence-based treatment and compliance to the treatment
plan (similarly to a disease management program that bene-
fited patients with HF25) patients who received the SAFETY
program are likely to incur greater costs in terms of hospital-
ization, medication, and outpatient care. The total estimated
NMB is $14 billion through monetizing the increased health
benefits (i.e. QALY), which shows the significant potential
gains for society via implementation of this health service in
Australia. Meanwhile, the estimated value of perfect informa-
tion is $217 million, which indicates the potential gain from
further research to reduce the uncertainty in the current
results. Although there is value in undertaking further
research to eliminate this uncertainty, delaying access to the
favorable intervention might also undermine the health ben-
efits of potential patients. In this regard, even though the
uncertainty of the estimates is not negligible and warrants
future research, the opportunity cost of delaying or, indeed,
not actioning these measures (i.e. loss of extended survival)
could justify their immediate implementation.
For a modelled economic analysis, an intervention’s effect
and the extrapolation of that effect beyond the trial duration
(which underpins the transition probability across modelled
health states) is a key determinant of the modelled outcome.
Conventionally, the transition probability is derived from the
aggregated outcome of the trial and then extrapolated or
assumed to be constant beyond the trial duration19. The
transition probabilities among health states presented in this
study were based on the individual patient-level information
and made the maximum use of trial data. The unobserved
and unknown covariance between variables are inherently
captured in such data; thus, the derived transition probability
has taken competing risks into consideration (i.e. the patient
faces the risk of rehospitalizations and death simultaneously).
In addition, patients can have a time-varying mortality after
each hospitalization event. For example, if the patient
Table 4. Results of base case and probabilistic sensitivity analyses.
Costs QALYs ICUR LYs ICER No. hospitalizations
Base case results
SAFETY program $94,953 3.99 5.86 14.85


















Abbreviation. QALYs, quality-adjusted life years; ICUR, incremental cost utility ratio; ICER, incremental cost effectiveness ratio.
Figure 2. Tornado diagram for a series of one-way deterministic sensitivity analysis (QALY as the outcome measure).
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remains hospitalization-free, the mortality of that health state
should vary with time (decreasing with time initially and
then eventually increasing with time and age). Use of the
trial-based individual patient-level data confers the advan-
tage of taking this into account. For the first 900 days, all the
transition probabilities were derived from the trial by count-
ing the number of patients that had transitted to a certain
health status at various time points. Survival beyond those
900 days was estimated with the parametric survival analysis
method. Likewise, the model parameters for cost and utility
weights were also generated from the SAFETY trial data. This
achieved the best outcome in terms of internal validity.
Given the ageing population worldwide, the prevalence of
NVAF is expected to escalate over time. Multidisciplinary
Figure 3. Incremental cost-effectiveness plane for QALY as the outcome measure.
Figure 4. Cost-effectiveness acceptability curve (QALY as the outcome measure). Abbreviations. AUD, Australian dollar; QALY, quality adjusted life year; WTP, will-
ingness to pay.
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management programs that promote the prescription of and
adherence to evidence-based treatment are needed, as the
management of NVAF is complex and multilayered26. Whilst
the SAFETY program was only delivered after the index hospi-
talization, the intervention’s effect was measured at a min-
imum follow-up time of 24months. If such an intervention is
implemented in the real world, it is highly likely that the
patients discharged from another hospitalization will receive
the SAFETY program again, which, in theory, could further
improve the cost-effectiveness of this intervention. The main
benefit from the SAFETY program is the extended survival but
not avoided hospitalizations, and such a trend was observed
during the trial period (supplementary figures A1 and A2 of
Stewart et al.12) An interesting finding from the DSA is that
the more the cost of prolonged hospitalization decreased, the
higher the resultant ICUR would be. This is because the
SAFETY program was associated with a lower probability of
extended hospital stay (see table 1 of Stewart et al.12)
Medicare Australia has dedicated items (item numbers 721
and 723) for chronic disease management to enable a GP to
plan and coordinate multidisciplinary, team-based healthcare.
However, this is not specifically designed for the management
of patients with atrial fibrillation and there are still gaps in the
care provision to improve the outcome of people with NVAF.
We believe this is the first modelled economic evaluation
assessing the long-term cost-effectiveness of a multidisciplinary
management program for patients with NVAF. An Australian
study reported cost saving of weight and risk-factor manage-
ment programs in patients with NVAF where the focus was not
to improve adherence to NVAF-related treatment27. In contrast,
economic evaluations of services for patients with HF are plen-
tiful. These services include remote monitoring programs
involving a HF nurse, HF nurse-led clinics, and HF disease man-
agement programs. In terms of the cost-effectiveness of these
services, Gohler et al.28 found that HF disease management
programs increased quality-adjusted life expectancy by an aver-
age of 0.19 years and increased the lifetime costs by e1,700,
with a corresponding ICER of e8,900/LY. Another study
reported that HF programs extended the average life expect-
ancy by 0.55 years with an additional cost of US$5,300 per
patient (ICER of US$9,700/LY) and the PSA calculated the mean
ICER as US$12,882/LY29. The service components incorporated
into these programs targeted for HF and NVAF are highly simi-
lar. For example, they unanimously included promotion of
pharmacological treatment as per guidelines and non-pharma-
cological management, provision of post-discharge care, pre-
scription of repeat examinations, and review management
plans5. Although these results are not directly comparable
(since the applied populations are different), they indeed sug-
gest that disease management programs could be a cost-effect-
ive approach to patients with chronic heart conditions and
ongoing care needs.
There are other integrated care models for NVAF like the
Atrial fibrillation Better Care (ABC) pathway program that
included stroke avoidance, symptom management, and car-
diovascular and other comorbidities management30–33. On the
other hand, the SAFETY program which aimed to optimize the
pharmacological treatment and management post-hospital
discharge with a transitional care focus differs to the ABC
pathway that provides an integrated care model for ongoing
management. However, these two care models can potentially
be synchronized to provide continuity in the care of patients
with NVAF post-discharge and for ongoing management.
This study is not without limitations. First, the trial only
followed patients for a median of 905 days (interquartile
range ¼ 773–1050). Extrapolation is necessary for post-inter-
vention survival for different health states. However, the rec-
ommended approaches were adopted to undertake this
analysis and the comparable results between the modelled
and observed overall survival can ease this concern to some
extent. Second, the utility weight of NVAF was derived from
the SAFETY trial and may not be the true utility weight due
to an insufficient sample size. Sensitivity analysis was per-
formed to examine this uncertainty. Third, perhaps most
importantly, the transition probability for the fourth and sub-
sequent rehospitalization was not estimated and was
assumed to be the same for the remaining time horizon.
This is due to the insufficient number of patients experienc-
ing more than four hospitalizations during the observation
period, which did not permit a reliable estimation of these
transitions. However, since the non-group-specific transition
probabilities were applied beyond the fourth rehospitaliza-
tion, this is considered conservative and not to favor the
SAFETY program. Last, the almost-3-year trial did find a trend
in survival gain between SAFETY and standard care; the lon-
ger-term modelled results projected that patients who
received the SAFETY program were likely to have better sur-
vival than those managed by the standard care. However,
the projected survival benefit warrants confirmation via lon-
ger-term study. Given the clinical need for better manage-
ment of patients with AF, the SAFETY program can be
implemented in real-world practice, but the key area of
uncertainty (i.e. what is identified from sensitivity analyses)
requires continuous monitoring and evaluation.
Conclusions
The SAFETY program has a high probability of being a cost-
effective program to manage patients with NVAF in the
Australian healthcare system. Although it is associated with
uncertainty that further research could potentially eliminate,
the current clinical needs warrant its implementation with
further evidence collected, particularly as it has the potential
to extend a patients days alive and out of hospital.
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